Kadimastem Ltd (KDST) - Total Assets
Based on the latest financial reports, Kadimastem Ltd (KDST) holds total assets worth ILA1.55 Million ILA (≈ $4.17K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See how leveraged is Kadimastem Ltd's balance sheet to measure how much of total assets are equity-financed.
Kadimastem Ltd - Total Assets Trend (2010–2024)
This chart illustrates how Kadimastem Ltd's total assets have evolved over time, based on quarterly financial data. Check KDST intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Kadimastem Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Kadimastem Ltd's total assets of ILA1.55 Million consist of 86.4% current assets and 13.7% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 72.0% |
| Accounts Receivable | ILA0.00 | 0.0% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Kadimastem Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KDST company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kadimastem Ltd's current assets represent 86.4% of total assets in 2024, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 72.0% of total assets in 2024, up from 32.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kadimastem Ltd Competitors by Total Assets
Key competitors of Kadimastem Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
ABL Bio Inc
KQ:298380
|
Korea | ₩280.93 Billion |
|
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
|
USA | $497.60 Million |
|
Ascletis Pharma Inc
F:2VJ
|
Germany | €2.07 Billion |
|
ABCELLERA BIOLOGICS
F:8QQ
|
Germany | €1.36 Billion |
Kadimastem Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.33 | 0.09 |
| Quick Ratio | 0.02 | 0.33 | 0.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-51.21 Million | ILA-9.09 Million | ILA-14.45 Million |
Kadimastem Ltd - Advanced Valuation Insights
This section examines the relationship between Kadimastem Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 118.49 |
| Latest Market Cap to Assets Ratio | 6.73 |
| Asset Growth Rate (YoY) | -60.6% |
| Total Assets | ILA3.30 Million |
| Market Capitalization | $22.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Kadimastem Ltd's assets at a significant premium (6.73x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Kadimastem Ltd's assets decreased by 60.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kadimastem Ltd (2010–2024)
The table below shows the annual total assets of Kadimastem Ltd from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA3.30 Million ≈ $8.84K |
-60.60% |
| 2023-12-31 | ILA8.37 Million ≈ $22.43K |
-33.01% |
| 2022-12-31 | ILA12.49 Million ≈ $33.48K |
-54.32% |
| 2021-12-31 | ILA27.34 Million ≈ $73.30K |
+153.40% |
| 2020-12-31 | ILA10.79 Million ≈ $28.93K |
+48.03% |
| 2019-12-31 | ILA7.29 Million ≈ $19.54K |
-50.13% |
| 2018-12-31 | ILA14.62 Million ≈ $39.18K |
+20.47% |
| 2017-12-31 | ILA12.13 Million ≈ $32.53K |
+154.71% |
| 2016-12-31 | ILA4.76 Million ≈ $12.77K |
-39.85% |
| 2015-12-31 | ILA7.92 Million ≈ $21.23K |
-34.15% |
| 2014-12-31 | ILA12.02 Million ≈ $32.24K |
-3.10% |
| 2013-12-31 | ILA12.41 Million ≈ $33.27K |
+186.85% |
| 2012-12-31 | ILA4.33 Million ≈ $11.60K |
-4.23% |
| 2011-12-31 | ILA4.52 Million ≈ $12.11K |
-14.73% |
| 2010-12-31 | ILA5.30 Million ≈ $14.20K |
-- |
About Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more